In a decision on 22 March in Teva and ors v AstraZeneca concerning a patent on a sustained release formulation of an anti-psychotic drug, Mr Justice Arnold revoked the patent due to obviousness.

In his IPKat blog, Darren Smyth draws comparisons between this decision and that of Actavis v Novartis, which involved a patent concerning a sustained release formulation of fluvastatin that was held to be obvious.